Producer
Anhui Newman Fine Chemicals
Chinese pharmaceutical and personal care carbomer producer; one of the largest non-Lubrizol carbomer manufacturers. Produces cross-linked polyacrylic acid (carbomer) for personal care and some pharmaceutical applications at lower price points than Lubrizol Carbopol. Growing market share as pharmaceutical formulators seek alternatives to Lubrizol after COVID-era supply shock.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Anhui Newman Fine Chemicals supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Anhui Newman Fine Chemicals makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Pharmaceutical Intermediates & APIs
55%Specialty Chemical Products
30%Research Chemicals & Custom Services
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Origin2022
Anhui Newman Fine Chemicals Co., Ltd. is part of Anhui Province's substantial pharmaceutical and fine chemicals manufacturing cluster — a regional concentration that developed as Chinese chemical industry expanded inland from coastal manufacturing zones. Anhui's chemical sector benefits from its location between Shanghai (eastern market access) and central China (raw material sourcing from inland), proximity to universities and research institutions in Hefei (home of University of Science and Technology of China, a major technical research center), and provincial government incentives for chemical industry development. Fine chemical companies in Anhui typically serve as intermediary processors in the global pharmaceutical supply chain: they purchase commodity petrochemical or agricultural feedstocks, perform multi-step organic synthesis to produce intermediates of moderate complexity, and sell these to API manufacturers who perform final synthesis steps. This position in the middle of the pharmaceutical value chain makes fine chemical companies like Anhui Newman difficult to track in public supply chain analyses — they are neither the commodity raw material (visible to commodity market researchers) nor the finished drug (visible to regulators), but the opaque middle layer where most pharmaceutical manufacturing value is added.
ChemicalBook ↗